Experimental Construction of BMP2 and VEGF Gene Modified Tissue Engineering Bone in Vitro
AbstractThe purpose of this study was to investigate the feasibility and advantages of constructing a novel tissue engineering bone, using β-tricalcium phosphate (β-TCP) and rat bone marrow mesenchymal stem cells (MSCs), modified with human bone morphogenetic protein 2 gene (hBMP2) and human vascular endothelial growth factor 165 gene (hVEGF165), through lentiviral transfection. Both genes were successfully co-expressed in the co-transfection group for up to eight weeks confirmed by enzyme-linked immunosorbent assay (ELISA). After seeding MSCs onto the scaffolds, scanning electron microscopy (SEM) observation showed that MSCs grew and proliferated well in co-transfection group at 7 and 14 days. There was no significant difference among all the groups in hoechst DNA assay for cell proliferation for 14 days after cell seeding (P > 0.05), but the highest alkaline phosphatase (ALP) activity was observed in the co-transfection group at 14 days after cell seeding (p < 0.01). These results demonstrated that it was advantageous to construct tissue engineering bone using β-TCP combined with MSCs lentivirally co-transfected with BMP2 and VEGF165, providing an innovative way for treating bone defects. View Full-Text
Share & Cite This Article
Jiang, J.; Fan, C.-Y.; Zeng, B.-F. Experimental Construction of BMP2 and VEGF Gene Modified Tissue Engineering Bone in Vitro. Int. J. Mol. Sci. 2011, 12, 1744-1755.
Jiang J, Fan C-Y, Zeng B-F. Experimental Construction of BMP2 and VEGF Gene Modified Tissue Engineering Bone in Vitro. International Journal of Molecular Sciences. 2011; 12(3):1744-1755.Chicago/Turabian Style
Jiang, Jia; Fan, Cun-Yi; Zeng, Bing-Fang. 2011. "Experimental Construction of BMP2 and VEGF Gene Modified Tissue Engineering Bone in Vitro." Int. J. Mol. Sci. 12, no. 3: 1744-1755.